BioCentury
ARTICLE | Strategy

Threshold to academia

How new vice chancellor Selick plans to reap rewards for UCSF innovations

June 14, 2017 7:19 PM UTC

By C. Simone Fishburn, Editor, BioCentury Innovations

In transitioning from industry to academia, former CEO of Threshold Pharmaceuticals Inc. Barry Selick wants to walk a fine line between the two worlds, increasing the returns on research investments for his new employer, UCSF, while pushing for an emphasis in innovation of quality over quantity...